Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes
Affiliations
- PMID: 16355599
Item in Clipboard
Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes
AIDS Read.
2005 Dec.
Abstract
A number of protease inhibitors (PIs) are dependent on an acidic gastric pH for optimal drug dissolution and absorption. As a result, the potential for negative drug interactions with acid-reducing agents exists and could lead to subtnerapeutic drug concentrations, viral breakthrough, and development of drug resistance. Pharmacokinetic evaluations of a number of PIs given with acid-reducing agents have been performed and show varying degrees of effect. Given the possibility of decreases in PI exposures, clinicians should be aware of the potential for a negative interaction when selecting PI-based HAART for patients taking acid-reducing agents.
Similar articles
-
Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.HIV Med. 2007 May;8(4):220-5. doi: 10.1111/j.1468-1293.2007.00456.x. HIV Med. 2007. PMID: 17461849
-
The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.Antivir Ther. 2006;11(7):923-9. Antivir Ther. 2006. PMID: 17302255
-
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.J Clin Virol. 2008 Feb;41(2):154-9. doi: 10.1016/j.jcv.2007.10.003. Epub 2007 Nov 19. J Clin Virol. 2008. PMID: 18024202
-
Protease inhibitor plasma concentrations in HIV antiretroviral therapy.Dan Med Bull. 2008 Nov;55(4):165-85. Dan Med Bull. 2008. PMID: 19232158 Review.
-
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.AIDS. 2009 Jan 28;23(3):279-91. doi: 10.1097/QAD.0b013e32831c54e5. AIDS. 2009. PMID: 19114854 Review.
Cited by
-
Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.J Neuroimmune Pharmacol. 2021 Mar;16(1):90-112. doi: 10.1007/s11481-019-09868-9. Epub 2019 Aug 6. J Neuroimmune Pharmacol. 2021. PMID: 31385157 Free PMC article. Review.
-
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.AIDS Patient Care STDS. 2011 Sep;25(9):509-15. doi: 10.1089/apc.2011.0113. Epub 2011 Jul 19. AIDS Patient Care STDS. 2011. PMID: 21770762 Free PMC article. Clinical Trial.
-
Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.Pharmacotherapy. 2011 Mar;31(3):253-61. doi: 10.1592/phco.31.3.253. Pharmacotherapy. 2011. PMID: 21361735 Free PMC article.
-
Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.Antimicrob Agents Chemother. 2007 Mar;51(3):958-61. doi: 10.1128/AAC.01203-06. Epub 2007 Jan 8. Antimicrob Agents Chemother. 2007. PMID: 17210768 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous